Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    Enhancing the Efficacy of Adenovirus-5 Vectored Ebola Virus Vaccines

    By Global Biodefense StaffMay 25, 2017
    Ebola Monoclonal Antibody Countermeasures
    Share
    Facebook LinkedIn Reddit Email

    The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Virology Division, Pathogenesis and Immunology Branch has been tasked by the Defense Threat Reduction Agency to investigate a potential for enhanced efficacy adenovirus-5 vectored Ebola Virus (EBOV) vaccines.

    One vaccine will express the glycoprotein (GP) of Ebola Virus (EBOV) and the other will express a multimerized CD40 Ligand (CD40L)/EBOV GP antigen.

    CD40L functions in a role that provides crucial information between cell types to generate productive immune responses.  The cognate receptor for CD40L and CD40 is expressed by antigen-presenting cells.

    CD40L, therefore, can be utilized to direct an antigen of interest to a specific cell type (i.e. antigen-presenting cells).  As antigen-presenting cells are pivotal initiators of immune responses, targeting an antigen of interest specifically to them – by virtue of CD40L – presents a means of efficient antigen delivery that can elicit robust immune responses.

    Furthermore, the biology behind CD40L and CD40 interactions results in a phenomenon known as cross-presentation, which increases the breadth of T cell responses that can be derived from vaccination. Multimerized formulations of CD40L-EBOV GP are essential as CD40 expression on antigen-presenting cells is best engaged by multiple CD40L molecules.

    Current Ebola EBOV vaccines utilize the GP of EBOV to elicit immune responses.  The goal is to evaluate the relative potency of EBOV GP vaccination in an Adenovirus-5 (Ad5) vector compared to an identically vectored EBOV GP that utilizes CD40L targeting.

    A contractor is sought to provide USAMRIID with two batches of vaccine in an Ad5 vector.  One shall express EBOV GP and the other shall express a multimerized construct of CD40L/EBOV GP.  Each batch will need to be sufficient to vaccinate 300 mice at a dose of 1×108 infectious units (IU) per mouse.

    The anticipated period of performance of the contract is a base year with four option years, beginning in July 2017.

    Solicitation Number: W81XWH17T0117. The response deadline is Jun 05, 2017 10:00 am Eastern.

    Source: FBO.gov

    Defense Threat Reduction Agency Ebola Emerging Threats Request for Quotes USAMRIID Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleUS Army Special Immunizations Program for Rift Valley Fever Vaccine
    Next Article Biodefense Headlines – May 29, 2017

    Related Stories

    Valley Fever: An Invisible Killer Expands Its Range in the American West

    November 17, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.